Report on key topics discussed at the latest Liquid Biopsy Annual Congress held in Madrid from November 19 to 21, 2023. #ISLB23 International Society of Liquid Biopsy Umberto Malapelle
Looking forward to learn more about the topics that will be discussed in Denver during #ISLB24 .
4oncommunity.com/en/in-depth-no…

Thanks to ESMO - Eur. Oncology ESMO Daily for highlighting our paper in Clinical Cancer Research Tumor Fraction #liquidbiopsy . This is an important concept to distinguish non shedders to non informative LB.
Lincoln Pasquina Hatim Husain
The Tisch Cancer Institute
Great comment by Umberto Malapelle
dailyreporter.esmo.org/news/liquid-bi…

A study illustrates a methodology that shows promise to distinguish true negative liquid biopsy results from indeterminate results that may benefit from follow-up tissue testing 🤞

dailyreporter.esmo.org/news/liquid-bi…

Umberto Malapelle Gianluca Russo Pasquale Pisapia

While osimertinib and afatinib are both active in #EGFR G719X mutant NSCLC, report Clinical Cancer Research shows that the E709X co-mutation mediates primary resistance to 3G EGFR TKIs and afatinib may be the better choice when present.

aacrjournals.org/clincancerres/…

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24 , out in Cancer Discovery today rb.gy/q484j9 Tweetorial👇

Un caso di paziente con adenocarcinoma e pregressa RT per metastasi encefalica, trattato con due cicli di CT e per 4/5 mesi con la combo #ipilimumab più #nivolumab . Ce ne parla Valerio Gristina.
UniPa
#LUAD #NSCLC
oncoinfo.it/rubriche/clini…

Thank you ESMO - Eur. Oncology IASLC #ELCC24 for a chance to present on #ctDNA driven Precision Oncology Trials in Lung Cancer alongside Dr. Leighl, Umberto Malapelle and Tetsuya Mitsudomi #LCSM International Society of Liquid Biopsy

FLAURA2 interim OS analysis: trend towards an OS benefit (HR 0.75; 95% CI 0.57, 0.97; p=0.0280) for osimertinib + platinum-pemetrexed chemotherapy versus osimertinib alone. #ELCC24 OncoAlert

Great scientific symposium on EGFR mutated NSCLC at the #ELCC24 with a great panel of experts discussing the challenges and opportunities in this setting in light of new treatment options. Umberto Malapelle Raffaele Califano Jordi Remon IASLC ESMO - Eur. Oncology

In to the lab - Fourth generation sequencing for methylation analysis in liquid biopsy: what else!
Unina Federico II Chantelle

Systematic review of TKI efficacy in NSCLC harboring uncommon EGFR mutations JTO & JTO CRR:

- 1836pts, 38 studies
- G719X, S768I, E709X, L747X; compound mtns; & PACC mtns: best ORR to 2nd-gen TKIs
- L861Q best ORR to 3rd gen TKI

Alfredo Addeo MD OncoAlert #LCSM

jto.org/article/S1556-…

#ESMOTAT24
🩸ctDNA applications 🩸
👉🏼 Marlene Thomas on strengths and weaknesses of #ctDNA Roche
👉🏼 Umberto Malapelle on #MRD
👉🏼 Sandi on Implementing broad panel in @NHS
👉🏼 Dr. SW Tan on #ctDNA in #ECT #drugdevelopment National Cancer Centre Singapore

Peptide-drug conjugates (PDCs) are the next in targeted therapy after antibody-drug conjugates (ADCs). Compared with ADCs, the core advantages of PDCs are enhanced tissue penetration, easier chemical synthesis, and lower production costs. sciencedirect.com/science/articl…

È un onore per il nostro gruppo annunciare che il Prof. Umberto Malapelle è stato nominato dallo #IASLC co-chair del #WCLC2025 , che si terrà a Barcellona insieme alla Prof. Jarushka Naidoo , alla Prof. Isabelle Opitz e alla Prof. Noemi Reguart 🌋 Unina Federico II

unina.it/-/54322565-il-…

Happy to report ctDNA analysis of PARADIGM Nature Medicine. Negative hyper selection enriched benefit of pani for CRC regardless of sidedness. Tumor location serve as surrogate for molecular type? Nature Portfolio ESMO - Eur. Oncology ASCO Takeda Oncology OncoAlert
nature.com/articles/s4159…

🎧Guests of the 4° episode
Prof. Umberto Malapelle, Department of Public Health, Chair of Predictive Molecular Pathology Lab at Unina Federico II.

Prof. Tania Labiano, Department of Pathological Anatomy at Complejo Hospitalario de Navarra, Spain.

👇Listen here👇4oncommunity.com/en/4oncommunit…

New study uncovers that ≈ a third of NSCLC patients develop specific mutations as acquired resistance to #immunotherapy , including alterations in STK11, B2M, APC,MTOR, KEAP1, & JAK1/2. ascopubs.org/doi/10.1200/JC…

New Research: Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy: Background

Consolidative thoracic… frontiersin.org/articles/10.33… #immunology

Out now on Frontiers - Immunology our retrospective study evaluating the impact of consolidative TRT in ES-SCLC under 1st line chemo-IO. A great effort of the LYONS (Lung Young Oncology Network Sud) group, founded by Fabiana Vitiello. Thanks Carminia Della Corte and Vito!
frontiersin.org/articles/10.33…